• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Sema4

Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration

by HIMSS22 Summary 03/16/2022 Leave a Comment

HIMSS22 Day 2 Roundup: Google Partners with MEDITECH, Microsoft’s Health Cloud Strategy Expansions,

Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can
Read More

Sema4, BioSymetrics Partner to Advance Data-Driven Drug Discovery

by Jasmine Pennic 02/22/2022 Leave a Comment

Mount Sinai Spinout Sema4 Launches to Revolutionize Clinical Diagnostics

What You Should Know: - Today, Sema4, a leader in AI-driven clinical data intelligence, announced that they have partnered with BioSymetrics, to accelerate the advancement of drug discovery and new treatments for patients and pharmaceutical companies. - Together the two will leverage Sema4’s Centrellis®, one of the largest and fastest-growing integrated health information platforms that includes approximately 12 million de-identified clinical records, and Elion, BioSymetrics’
Read More

Sema4 Acquires GeneDx for $623M to Strengthen AI-Driven Genomic Platform

by Fred Pennic 01/18/2022 Leave a Comment

Sema4 Acquires GeneDx for $623M to Strengthen AI-Driven Genomic Platform

What You Should Know: - Today, Sema4 (Nasdaq: SMFR), a health intelligence company, announced it has signed a definitive agreement to acquire GeneDx, a leader in genomic testing and analysis, at a purchase price representing approximately $623 million, strengthening its market-leading health intelligence and genomic screening offerings. - The combined company is projected to deliver $350 million in pro forma 2022 revenue. In connection with the acquisition,
Read More

Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity

by Healthcare Growth Partners (HGP) 04/12/2021 Leave a Comment

Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity

The first quarter of 2021 has been one of investor optimism as the vaccine rollout continues ahead of expectations and economic activity begins to accelerate in response.  Within the Health IT industry, the already strong investment and M&A trends seen in 2020 have only accelerated.  Over the course of the quarter, we observed $7 billion in private equity and venture capital investment across 158 companies.  By comparison, Q1 of 2020 saw $3.2 billion and 127 investments.  Health IT
Read More

Analysis: July Health IT M&A Activity; Public Company Performance

by Healthcare Growth Partners (HGP) 08/07/2020 Leave a Comment

Analysis: July Health IT M&A Activity; Public Company Performance

– Healthcare Growth Partners’ (HGP) summary of Health IT/digital health mergers & acquisition (M&A) activity, and public company performance during the month of July 2020. While a pandemic ravages the country, technology valuations are soaring.  The Nasdaq hit an all-time high during the month of July, sailing through the 10,000 mark to post YTD gains of nearly 20%, representing a 56% increase off the low water mark on March 23.  More notably, the Nasdaq has outperformed
Read More

Mount Sinai Spinout Sema4 Launches to Revolutionize Clinical Diagnostics

by HITC Staff 06/01/2017 Leave a Comment

Mount Sinai Spinout Sema4 Launches to Revolutionize Clinical Diagnostics

Sema4, a new startup that has spun out of Mount Sinai Health System has officially launched today that aims to use genomic and clinical data to empower more informed health decisions and enhance care and wellness. Formerly the Mount Sinai Genetic Testing Lab at the Icahn School of Medicine at Mount Sinai, Sema4 is constructing a more comprehensive picture of health by combining a wealth of clinical experience that informs the answers that patients and providers are seeking, the world-class
Read More

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |